about
Evaluation of meglumine gadoterate-enhanced MR angiography (MRA) compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease: a pooled analysis of data from two clinical trials.How stereological analysis of vascular morphology can quantify the blood volume fraction as a marker for tumor vasculature: comparison with magnetic resonance imaging.Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.Septic arthritis: monitoring with USPIO-enhanced macrophage MR imaging.Washout of mass-like benign breast lesions at dynamic magnetic resonance imaging.Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography.Contrast-enhanced magnetic resonance angiography in rabbits: evaluation of the gadolinium-based agent p846 and the iron-based blood pool agent p904 in comparison with gadoterate meglumine.Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine.Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.Re: Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.Evaluation of contrast-enhanced magnetic resonance angiography (MRA) using Gd-DOTA compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease.Signal-inducing bone cements for MRI-guided spinal cementoplasty: evaluation of contrast-agent-based polymethylmethacrylate cements.Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy?Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in miceTolerability of gadobenate dimeglumine in a patient with reported allergy to gadoterate meglumine
P921
Q34100385-20430594-212B-46B1-B54A-B9503AC40BD1Q35800491-A0CF36A0-ABDF-47A2-8027-865FE8A35854Q36755878-24118113-1879-4D9E-BF2B-2523BE62C080Q37282521-6F78AB5A-1650-42AD-A7FD-A55DEB0FA89EQ37845599-C775EF81-3B35-4B9C-8B9B-7A0643A2C28CQ38010634-492DDAA2-7BBE-4A76-AD25-58139EF685C3Q40033109-670A0834-3291-4843-91B5-78BC4A9E8171Q46269867-07760818-84AD-4BFA-9B50-5312C0E8F1D4Q46321019-7BEFA2BA-4411-413E-BBDF-B27A8A870CB0Q46345799-BD1D1238-9DB5-4A62-B2AA-1C2D1352D50BQ46883857-0E5F75BA-3B19-4DFD-B78D-B582CA763D47Q47310653-02CED1F2-C884-4DF6-9174-123E3F84BD37Q47357272-637DD16B-788E-49F4-8344-87354C27C9F1Q51570082-6E1C8C6C-2028-430E-976D-561E2DA4FA17Q52893077-124151DA-994C-4CA0-BAB2-E76BF08B4BA8Q56772911-BA7EF1FE-D810-4F68-BF99-62C9DC49B6BAQ82283317-592BEE05-9AF3-4C15-BD19-84402660F5D0Q82640858-210161C2-F740-4C9B-B3EE-5E6125428E61
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
gadoterate meglumine
@en
type
label
gadoterate meglumine
@en
altLabel
Gadolinium-DOTA meglumine
@en
Gd-DOTA meglumine
@en
Meglumine gadopentate
@en
Meglumine gadoterate
@en
prefLabel
gadoterate meglumine
@en
P486
P662
P665
P683
P2017
CNC[C@@H]([C@H]([C@@H]([C@@H]( ...... ])CC(=O)[O-])CC(=O)[O-].[Gd+3]
P2067
P2115
N0000188988
P231
92943-93-6
P233
CNCC(C(C(C(CO)O)O)O)O.C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]
P234
1S/C16H28N4O8.C7H17NO5.Gd/c21- ...... ;+3/p-3/t;4-,5+,6+,7+;/m.0./s1
P235
RYHQMKVRYNEBNJ-BMWGJIJESA-K
P274
C₂₃H₄₂GdN₅O₁₃
P2868
P2892
P3117
DTXSID80918856
P3345
P486
P652
L0ND3981AG